Serpin A1
Serpin A1 Molecule Information
Name:Alpha-1-antiproteinase
Target Synonym:PRO0684,SPAAT,SERPINA1,Alpha-1-antiproteinase,PRO2209,Serpin Family A Member 1,alpha 1-Antitrypsin,Protease Inhibitor 1 (Anti-Elastase), Alpha-1-Antitrypsin,Alpha-1 Protease Inhibitor,Serpin A1,AAT,PI,Serpin Peptidase Inhibitor Clade A (Alpha-1antiprotein
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved
Serpin A1 Protein Product ListCompare or Buy
Serpin A1 Molecule Synonym Name
SerpinA1,PI,A1A,AAT,PI1,A1AT,MGC9222,PRO2275,MGC23330,alpha1AT,SPAAT
Serpin A1 Molecule Background
Serpin A1 is also known as Alpha-1-antitrypsin (A1AT), serum trypsin inhibitor, alpha-1 proteinase inhibitor (A1PI), AAT, which belongs to the serpin family. Most serpins inactivate enzymes by binding to them covalently, requiring very high levels to perform their function. Like all serine protease inhibitors, A1AT has a characteristic secondary structure of beta sheets and alpha helices. Serpin A1 / A1AT is inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form of SerpinA1 inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin. Serpin A1 / A1AT protects tissues from enzymes of inflammatory cells, especially neutrophil elastase. Defects in SERPINA1 are the cause of alpha-1-antitrypsin deficiency (A1ATD).
Serpin A1 References
Serpin A1 Public Drug Information
Name |
Research Code |
Research Phase |
Company |
First Brand Name |
First Approved Country |
First Indication |
First Approved Company |
First Approved Date |
Indications |
Clinical Trials |
Alfalastin (LFB SA) |
|
Approved |
Lfb Biotechnologies |
Alfalastin |
France |
alpha 1-Antitrypsin Deficiency |
s:19:"Lfb Biotechnologies"; |
2005-08-01 |
alpha 1-Antitrypsin Deficiency |
Details
|
Serpin A1 Clinical Drug Information
Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
VX-864 |
VX-864 |
Phase 2 Clinical |
Vertex Pharmaceuticals Incorporated |
alpha 1-Antitrypsin Deficiency |
Details
|
Alpha-1 antitrypsin (Kalytera Therapeutics) |
|
Clinical |
Clalit Health Services |
|
Details
|
Belcesiran |
DCR-A1AT |
Phase 2 Clinical |
Dicerna Pharmaceuticals |
alpha 1-Antitrypsin Deficiency; Liver Diseases |
Details
|
ARO-AAT |
TAK-999; ARO-AAT |
Phase 3 Clinical |
Arrowhead Pharmaceuticals |
alpha 1-Antitrypsin Deficiency |
Details
|